Login to Your Account



Financings NEWS

SAN DIEGO – When it comes to big-pharma strategic corporate venture capital (CVC), biotech entrepreneurs should cast a wide net and be unafraid of multiple funders, but beware build-to-buy arrangements if the first money isn't plenty.

DUBLIN – Gamida Cell Ltd. took in $40 million in a new private financing round to enable it to complete an ongoing phase III pivotal trial of its Nicord umbilical cord blood expansion technology and to support preparations for its commercialization.

Checkmate Pharmaceuticals Inc. might be the only immuno-oncology (I-O) company that's not attending the BIO International Convention in San Diego.

More Financings Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: